← Back to Search

Unknown

UBX1325 for Age-Related Macular Degeneration

Phase 2
Waitlist Available
Research Sponsored by Unity Biotechnology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through 48 weeks
Awards & highlights

Study Summary

This trial will test if it is safe to give patients with wet AMD another injection of UBX1325.

Eligible Conditions
  • Age-Related Macular Degeneration (AMD)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through 48 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and through 48 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Treatment emergent adverse events (TEAEs) will be evaluated for ocular and systemic safety and tolerability of a repeat IVT injection of UBX1325 compared to active control
Secondary outcome measures
Adverse events (safety)
Change in best corrected visual acuity (BCVA) from Baseline over time
Change in central subfield thickness (CST) from Baseline over time as assessed by SD-OCT and read by a Central Reading Center

Side effects data

From 2020 Phase 4 trial • 26 Patients • NCT03022292
4%
Retinal detachment
4%
Myelodysplastic syndrome
4%
Pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
IAI Treatment

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: UBX1325Experimental Treatment1 Intervention
Group II: Aflibercept (EYLEA ®)Active Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
UBX1325 injection 50 μL
2022
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

Unity Biotechnology, Inc.Lead Sponsor
8 Previous Clinical Trials
611 Total Patients Enrolled
Sharon Klier, MD, MPHStudy DirectorUnity Biotechnology, Inc.
2 Previous Clinical Trials
105 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are enrolled in this clinical experiment?

"To successfully complete this clinical trial, 46 individuals meeting the requirements for inclusion must be recruited. Participants can find participating medical sites at Wilmer Eye Institute located in Baltimore, MD and Retina-Vitreous Associates Medical Group situated in Beverly Hills, IL."

Answered by AI

To what extent could UBX1325 be detrimental to those taking it?

"Our team at Power has rated UBX1325's safety as a 2; this assessment is based on the lack of evidence supporting efficacy, though there are some encouraging signs related to its security."

Answered by AI

Are there any openings for prospective participants in this clinical experiment?

"Affirmative. Data hosted on clinicaltrials.gov confirms that this medical study, which was initially published March 2nd 2022, is actively seeking participants. In total there are 46 slots available across 26 different sites."

Answered by AI

How widespread is the access to this research endeavor?

"Wilmer Eye Institute at John Hopkins University in Baltimore, Retina-Vitreous Associates Medical Group in Beverly Hills, and Salehi Retina Institute are amongst the 26 participating sites for this medical trial. Additionally, there are numerous other locations recruiting patients as well."

Answered by AI
~17 spots leftby Mar 2025